BNTX logo

BNTXBioNTech SE - ADR

$89.52
$3.39
(3.94%)
Today
Closed $89.54
$0.02
(0.02%)
After Hours
Updated: 04:16 PM EDT
EarningsAug 4
Mkt Cap$21.79B
Vol2.66M
News
all
press releases
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Zacks
News Placeholder
More News
News Placeholder
Investors Are Watching This High-Stakes Corner of Biotech
The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX
24-7 Market News
News Placeholder
The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers
Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX
24-7 Market News
News Placeholder
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
Zacks
News Placeholder
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.
Zacks
News Placeholder
Wells Fargo & Company Cuts BioNTech (NASDAQ:BNTX) Price Target to $140.00
Wells Fargo & Company lowered their price target on shares of BioNTech from $150.00 to $140.00 and set an "overweight" rating for the company in a report on Wednesday...
MarketBeat
News Placeholder
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eighteen research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold re...
MarketBeat
News Placeholder
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Zacks
News Placeholder
BioNTech Q1 Earnings Call Highlights
BioNTech (NASDAQ:BNTX) executives used the company's first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical...
MarketBeat
News Placeholder
BioNTech (NASDAQ:BNTX) Announces Earnings Results
BioNTech (NASDAQ:BNTX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($2.26) earnings per share for the quarter, topping analysts' consensus estimates of...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.